Benitec Biopharma Inc Quick Ratio (BNTC) starting from the first quarter 2026 to first quarter 2025, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket
 


Benitec Biopharma Inc   (NASDAQ: BNTC)

Benitec Biopharma Inc 's Quick Ratio

BNTC's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the first quarter 2026, Quick Ratio fell to 18.38 below Benitec Biopharma Inc average.

Within Major Pharmaceutical Preparations industry Benitec Biopharma Inc booked the highest Quick Ratio than Benitec Biopharma Inc in the first quarter 2026. While Quick Ratio total ranking has improved so far during the Q1 2026 to 18, from total ranking in the fourth quarter 2026 at 58.

Explain Quick Ratio?
How much Cash & cash equivalents BNTC´s has?
What are BNTC´s Current Liabilities?




API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/BNTC/financial-strength
https://api.csimarket.com/api/v1/companies/BNTC/fundamentals
https://api.csimarket.com/api/v1/companies/BNTC/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
BNTC Quick Ratio (Sep 30 2026)
Q1
(Jun 30 2026)
Q4
(Mar 31 2026)
Q3
(Dec 31 2025)
Q2
(Sep 30 2025)
Q1
Y / Y Current Liabilities Change 409.78 %
Y / Y Cash & cash equivalent Change 86.57 %
Quick Ratio MRQ 18.38
BNTC's Total Ranking # 18
Seq. Current Liabilities Change 1634.9 %
Seq. Cash & cash equivalent Change -2 %



Quick Ratio first quarter 2026 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 0
Healthcare Sector # 0
Overall Market # 18


Quick Ratio Statistics
High Average Low
325.45 23.06 0.63
(Jun 30 2026)   (Dec 31 2023)




Financial Statements
Benitec Biopharma Inc 's Current Liabilities $ 10 Millions Visit BNTC's Balance sheet
Benitec Biopharma Inc 's Cash & cash equivalent $ 176 Millions Visit BNTC's Balance sheet
Source of BNTC's Sales Visit BNTC's Sales by Geography


Cumulative Benitec Biopharma Inc 's Quick Ratio

BNTC's Quick Ratio for the trailling 12 Months

BNTC Quick Ratio

(Sep 30 2026)
12 Months
(Jun 30 2026)
12 Months
(Mar 31 2026)
12 Months
(Dec 31 2025)
12 Months
(Sep 30 2025)
12 Months
Y / Y Current Liabilities TTM Growth 1.49 %
Y / Y Cash & cash equivalent TTM Growth 84.21 %
Quick Ratio TTM 42.97
Total Ranking TTM # 2089
Seq. Current Liabilities TTM Growth 107.75 %
Seq. Cash & cash equivalent TTM Growth 14.69 %


On the trailing twelve months basis Due to in Current Liabilities in the Q1 2026 to $9.59 millions, cumulative Quick Ratio decreased to 42.97 above the BNTC average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 372 other companies have achieved higher Quick Ratio than Benitec Biopharma Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the fourth quarter 2026 from 1905 to 2089.

Explain Quick Ratio?
How much Cash & cash equivalents BNTC´s has?
What are BNTC´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 373
Healthcare Sector # 694
Within the Market # 2089


trailing twelve months Quick Ratio Statistics
High Average Low
53.35 10.55 2.35
(Mar 31 2026)   (Jun 30 2023)




Companies with similar Quick Ratio in the quarter ending Sep 30 2026, within Major Pharmaceutical Preparations Industry Quick RatioSep 30 2026 MRQ Cash & cash equivalentSep 30 2026 MRQ Current Liabilities
Enliven Therapeutics Inc   45.41 $ 884.351  Millions$ 19.473  Millions
Vyne Therapeutics Inc   41.29 $ 268.860  Millions$ 6.511  Millions
Bicara Therapeutics Inc   40.75 $ 442.346  Millions$ 10.856  Millions
Xbiotech Inc   39.02 $ 105.037  Millions$ 2.692  Millions
Tango Therapeutics Inc   38.85 $ 977.503  Millions$ 25.164  Millions
Trevi Therapeutics Inc   38.05 $ 299.408  Millions$ 7.869  Millions
Fulcrum Therapeutics Inc   35.70 $ 306.545  Millions$ 8.587  Millions
Boundless Bio Inc   33.60 $ 62.894  Millions$ 1.872  Millions
Avalyn Pharma Inc   32.64 $ 422.814  Millions$ 12.955  Millions
Immix Biopharma Inc   30.89 $ 336.303  Millions$ 10.889  Millions
Minerva Neurosciences Inc   30.46 $ 76.945  Millions$ 2.526  Millions
Contineum Therapeutics Inc   30.45 $ 244.484  Millions$ 8.028  Millions
Pasithea Therapeutics Corp   29.91 $ 82.419  Millions$ 2.756  Millions
Latigo Biotherapeutics, Inc.  28.73 $ 401.241  Millions$ 13.964  Millions
Amylyx Pharmaceuticals Inc   26.44 $ 768.132  Millions$ 29.048  Millions
Climb Bio Inc   25.98 $ 205.423  Millions$ 7.906  Millions
Prothena Corporation Public Limited Company  23.73 $ 271.368  Millions$ 11.434  Millions
Silo Pharma Inc  22.91 $ 8.051  Millions$ 0.351  Millions
Innoviva Inc   22.67 $ 1,134.297  Millions$ 50.030  Millions
Silence Therapeutics Plc  22.00 $ 247.659  Millions$ 11.259  Millions
Kailera Therapeutics Inc   21.40 $ 901.454  Millions$ 42.116  Millions
Cryoport inc   20.47 $ 653.343  Millions$ 31.911  Millions
Roivant Sciences Ltd   20.30 $ 5,683.045  Millions$ 279.911  Millions
Disc Medicine Inc   19.87 $ 682.816  Millions$ 34.360  Millions
Relmada Therapeutics Inc  19.30 $ 202.123  Millions$ 10.474  Millions
Mbx Biosciences Inc   19.14 $ 481.594  Millions$ 25.167  Millions
Telomir Pharmaceuticals Inc   19.07 $ 4.516  Millions$ 0.237  Millions
Equillium Inc   18.92 $ 53.322  Millions$ 2.819  Millions
Onkure Therapeutics Inc   18.58 $ 163.305  Millions$ 8.789  Millions
Benitec Biopharma Inc   18.38 $ 176.368  Millions$ 9.594  Millions

Date modified: 2026-11-14T08:46:18+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.